NPPA fixes retail prices for 41 drug combinations, including empagliflozin

The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 41 drug combinations, including 18 variants of the off-patent diabetes drug empagliflozin, originally developed by German pharmaceutical company Boehringer Ingelheim.

The move follows the expiry of empagliflozin’s patent on March 11, which opened the market to multiple generic versions by pharmaceutical companies. The launch of these variants has led to a significant 80 to 85 per cent drop in prices, prompting regulatory action to fix retail rates.

Last month, the authority had fixed retail prices for another 36 variants and combinations of empagliflozin.

The updated list includes anti-diabetic combinations involving empagliflozin with linagliptin, glimepiride, sitagliptin, and metformin hydrochloride, manufactured and marketed by pharmaceutical companies such as Blue Cross Laboratories, Torrent Pharma, Cadila, Glenmark, and Alkem Laboratories.

It also includes a combination of clindamycin and nicotinamide gel, which is used to treat acne, and multivitamin tablets containing iron, folic acid, and cyanocobalamin syrup.

Related Posts

  • Pharma
  • July 16, 2025
  • 126 views
Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

  • Pharma
  • July 16, 2025
  • 40 views
Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

The pharma sector will be in focus on July 16, after Donald Trump said that pharmaceuticals tariffs would be implemented soon. Shares of pharmaceutical companies traded flat on Wednesday, July…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Pharma stocks hover near flatline even as Trump hints at new tariffs by July-end

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.

Sun Pharma reaches settlement with Incyte Corporation, launches Leqselvi in U.S.